| NCT04414969 |
Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04414969 |
Recruiting |
Hunan Cancer Hospital |
2022-07-01 |
| NCT04217317 |
CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT04217317 |
Recruiting |
Wake Forest University Health Sciences |
2022-06-30 |
| NCT03947255 |
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03947255 |
Recruiting |
Seattle Genetics, Inc. |
2024-12-31 |
| NCT03552692 |
Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03552692 |
Active, not recruiting |
Fondazione Italiana Linfomi ONLUS |
2020-08-31 |
| NCT03409432 |
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03409432 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2021-04-30 |
| NCT03380026 |
Mechlorethamine Induced Contact Dermatitis Avoidance Study |
https://ClinicalTrials.gov/show/NCT03380026 |
Recruiting |
Rochester Skin Lymphoma Medical Group, PLLC |
2019-12-13 |
| NCT03363555 |
SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03363555 |
Active, not recruiting |
Jiangsu HengRui Medicine Co., Ltd. |
2019-06-30 |
| NCT03357224 |
PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT03357224 |
Recruiting |
European Organisation for Research and Treatment of Cancer - EORTC |
2021-09-30 |
| NCT03333486 |
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer |
https://ClinicalTrials.gov/show/NCT03333486 |
Recruiting |
Roswell Park Cancer Institute |
2022-09-06 |
| NCT03321890 |
Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT03321890 |
Recruiting |
Sun Yat-sen University |
2020-12-01 |
| NCT03292406 |
A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT03292406 |
Active, not recruiting |
Galderma R&D |
2020-09-30 |
| NCT03278782 |
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin |
https://ClinicalTrials.gov/show/NCT03278782 |
Active, not recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03268889 |
Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma) |
https://ClinicalTrials.gov/show/NCT03268889 |
Recruiting |
The First Affiliated Hospital of Soochow University |
2020-06-15 |
| NCT03263637 |
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies |
https://ClinicalTrials.gov/show/NCT03263637 |
Active, not recruiting |
AstraZeneca |
2021-12-31 |
| NCT03259503 |
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT03259503 |
Recruiting |
M.D. Anderson Cancer Center |
2023-07-01 |
| NCT03246750 |
B-MAD Chemotherapy in Newly-diagnosed Extranodal NK/ T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03246750 |
Recruiting |
The Thai Lymphoma Study Group |
2021-06-30 |
| NCT03240211 |
Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL |
https://ClinicalTrials.gov/show/NCT03240211 |
Recruiting |
Columbia University |
2019-12-31 |
| NCT03228836 |
Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03228836 |
Active, not recruiting |
Innovent Biologics (Suzhou) Co. Ltd. |
2018-02-07 |
| NCT03218683 |
Study of AZD5991 in Relapsed or Refractory Haematologic Malignancies. |
https://ClinicalTrials.gov/show/NCT03218683 |
Active, not recruiting |
AstraZeneca |
2022-01-11 |
| NCT03217643 |
CHP-BV Followed by Consolidation With High-dose Therapy / ASCT as Frontline Treatment of Patients With EATL Type 1. |
https://ClinicalTrials.gov/show/NCT03217643 |
Recruiting |
Imagine Institute |
2021-09-30 |
| NCT03212937 |
Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03212937 |
Active, not recruiting |
National Cancer Centre, Singapore |
2020-02-29 |
| NCT03210662 |
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03210662 |
Recruiting |
M.D. Anderson Cancer Center |
2020-11-30 |
| NCT03192202 |
AFM13 in Relapsed/Refractory Cutaneous Lymphomas |
https://ClinicalTrials.gov/show/NCT03192202 |
Recruiting |
Columbia University |
2020-08-31 |
| NCT03161223 |
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma |
https://ClinicalTrials.gov/show/NCT03161223 |
Recruiting |
Columbia University |
2021-02-28 |
| NCT03154918 |
GLIDE Regimen Followed by ASCT for Aggressive NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03154918 |
Recruiting |
Sichuan University |
2020-12-31 |
| NCT03154710 |
Relevance of a Web-mediated Follow up in Patients Having a Lymphoma With a High Risk of Relapse in Complete or Partial Response |
https://ClinicalTrials.gov/show/NCT03154710 |
Recruiting |
Weprom |
2022-01-31 |
| NCT03150602 |
A Pralatrexate Study in Asian Patients With Peripheral T-cell Lymphoma After Prior Therapy |
https://ClinicalTrials.gov/show/NCT03150602 |
Recruiting |
Taiwan Mundipharma Pharmaceuticals Ltd. |
2020-12-31 |
| NCT03141203 |
Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03141203 |
Active, not recruiting |
University of Birmingham |
2020-08-31 |
| NCT03116659 |
CTCL Directed Therapy |
https://ClinicalTrials.gov/show/NCT03116659 |
Recruiting |
James J. Peters Veterans Affairs Medical Center |
2020-12-30 |
| NCT03113500 |
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03113500 |
Recruiting |
City of Hope Medical Center |
2021-01-21 |
| NCT03109353 |
Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease |
https://ClinicalTrials.gov/show/NCT03109353 |
Active, not recruiting |
St. Olavs Hospital |
2020-09-30 |
| NCT03071822 |
Combination Chemotherapy Including Cisplatin, Ifosfamide, Gemcitabine, L-asparaginase, Etoposide and Dexamethasone as Treatment of Newly Diagnosed and Relapsed/Refractory Peripheral T Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03071822 |
Recruiting |
The University of Hong Kong |
2021-07-31 |
| NCT03052933 |
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL |
https://ClinicalTrials.gov/show/NCT03052933 |
Active, not recruiting |
Chonnam National University Hospital |
2021-12-31 |
| NCT03046953 |
Avelumab in Relapsed and Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03046953 |
Recruiting |
University of Birmingham |
2020-08-31 |
| NCT03035331 |
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT03035331 |
Recruiting |
Mayo Clinic |
2021-02-15 |
| NCT03017820 |
VSV-hIFNbeta-NIS in Treating Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03017820 |
Recruiting |
Mayo Clinic |
2021-01-15 |
| NCT03011814 |
Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03011814 |
Recruiting |
City of Hope Medical Center |
2023-03-08 |
| NCT02987244 |
Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02987244 |
Recruiting |
Peking Union Medical College Hospital |
2020-03-31 |
| NCT02978625 |
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers |
https://ClinicalTrials.gov/show/NCT02978625 |
Recruiting |
National Cancer Institute (NCI) |
2021-06-01 |
| NCT02955589 |
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) |
https://ClinicalTrials.gov/show/NCT02955589 |
Active, not recruiting |
HUYA Bioscience International |
2018-12-31 |
| NCT02953652 |
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT02953652 |
Active, not recruiting |
HUYA Bioscience International |
2019-04-30 |
| NCT02927925 |
A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer/T-Cell Lymphoma (NKTCL), Nasal Type |
https://ClinicalTrials.gov/show/NCT02927925 |
Completed |
Janssen Research & Development, LLC |
2020-01-02 |
| NCT02879526 |
Chidamide Combined With Cyclophosphamide, Prednisone, Thalidomide in Treatment of Fragile Patients With Relapse/Refratory Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02879526 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2019-06-30 |
| NCT02859402 |
Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02859402 |
Recruiting |
Keimyung University Dongsan Medical Center |
2019-12-31 |
| NCT02825147 |
Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02825147 |
Completed |
Ruijin Hospital |
2016-03-31 |
| NCT02809573 |
Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT02809573 |
Completed |
Chipscreen Biosciences, Ltd. |
2019-01-08 |
| NCT02797470 |
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT02797470 |
Recruiting |
AIDS Malignancy Consortium |
2021-09-30 |
| NCT02783625 |
Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02783625 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-05-31 |
| NCT02764281 |
MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02764281 |
Completed |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-02-29 |
| NCT02689453 |
Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL) |
https://ClinicalTrials.gov/show/NCT02689453 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-01-31 |
| NCT02676778 |
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02676778 |
Completed |
Eisai Inc. |
2019-04-24 |
| NCT02653976 |
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT02653976 |
Active, not recruiting |
Solasia Pharma K.K. |
2019-12-31 |
| NCT02652715 |
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02652715 |
Completed |
Mayo Clinic |
2018-12-21 |
| NCT02633020 |
Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients With Type II Refractory Celiac Disease |
https://ClinicalTrials.gov/show/NCT02633020 |
Completed |
Amgen |
2017-04-11 |
| NCT02631239 |
MESA Versus ESA in the Treatment of Early Stage NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02631239 |
Recruiting |
Ruijin Hospital |
2020-11-30 |
| NCT02616965 |
A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02616965 |
Recruiting |
Fox Chase Cancer Center |
2021-12-31 |
| NCT02594267 |
A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT02594267 |
Active, not recruiting |
Acrotech Biopharma LLC |
2020-08-31 |
| NCT02593045 |
Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) |
https://ClinicalTrials.gov/show/NCT02593045 |
Active, not recruiting |
Innate Pharma |
2019-12-31 |
| NCT02588651 |
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) |
https://ClinicalTrials.gov/show/NCT02588651 |
Recruiting |
Case Comprehensive Cancer Center |
2020-08-31 |
| NCT02576496 |
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT02576496 |
Recruiting |
Mundipharma-EDO GmbH |
2021-03-31 |
| NCT01716806 |
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01716806 |
Recruiting |
Seattle Genetics, Inc. |
2021-09-30 |
| NCT02567656 |
Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02567656 |
Completed |
Rhizen Pharmaceuticals SA |
2018-03-31 |
| NCT02561273 |
Combination Chemotherapy and Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT02561273 |
Active, not recruiting |
University of Nebraska |
2020-10-31 |
| NCT02560441 |
Trial of IPGDP Regimen Chemotherapy in Patients With Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type |
https://ClinicalTrials.gov/show/NCT02560441 |
Recruiting |
Chinese Academy of Medical Sciences |
2022-09-30 |
| NCT02546440 |
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT02546440 |
Recruiting |
Universitätsmedizin Mannheim |
2020-09-30 |
| NCT02542124 |
NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) |
https://ClinicalTrials.gov/show/NCT02542124 |
Active, not recruiting |
Neumedicines Inc. |
2019-02-28 |
| NCT02535247 |
Study of MK-3475 Alone or in Combination With Copanlisib in Relapsed or Refractory NK and T-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02535247 |
Recruiting |
Fox Chase Cancer Center |
2020-12-31 |
| NCT02533700 |
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL |
https://ClinicalTrials.gov/show/NCT02533700 |
Active, not recruiting |
Shandong Provincial Hospital |
2019-05-31 |
| NCT02520791 |
Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02520791 |
Recruiting |
National Cancer Institute (NCI) |
2020-12-31 |
| NCT02512497 |
Romidepsin Maintenance After Allogeneic Stem Cell Transplantation |
https://ClinicalTrials.gov/show/NCT02512497 |
Recruiting |
Ohio State University Comprehensive Cancer Center |
2020-12-31 |
| NCT02495415 |
Trial of Intravenous Fenretinide Emulsion for Patients With Relapsed/Refractory Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02495415 |
Recruiting |
CerRx, Inc. |
2021-07-31 |
| NCT02464228 |
Investigation of Tipifarnib in Treatment of Subjects With PTCL That Have Not Responded to Standard Therapy. |
https://ClinicalTrials.gov/show/NCT02464228 |
Active, not recruiting |
Kura Oncology, Inc. |
2021-01-15 |
| NCT02448381 |
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |
https://ClinicalTrials.gov/show/NCT02448381 |
Active, not recruiting |
Soligenix |
2019-12-31 |
| NCT02445404 |
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL |
https://ClinicalTrials.gov/show/NCT02445404 |
Recruiting |
Samsung Medical Center |
2020-06-30 |
| NCT02432235 |
Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02432235 |
Completed |
ADC Therapeutics S.A. |
2019-10-24 |
| NCT02424968 |
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma |
https://ClinicalTrials.gov/show/NCT02424968 |
Active, not recruiting |
Stanford University |
2020-07-31 |
| NCT02424045 |
Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02424045 |
Completed |
Samsung Medical Center |
2017-09-30 |
| NCT02362997 |
Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL |
https://ClinicalTrials.gov/show/NCT02362997 |
Recruiting |
Dana-Farber Cancer Institute |
2020-09-30 |
| NCT02342782 |
Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02342782 |
Active, not recruiting |
City of Hope Medical Center |
2020-12-31 |
| NCT02341209 |
Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02341209 |
Recruiting |
Rochester General Hospital |
2020-02-06 |
| NCT02309580 |
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02309580 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2020-12-31 |
| NCT02276248 |
Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02276248 |
Completed |
Chinese Academy of Medical Sciences |
2016-12-31 |
| NCT02273739 |
Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation |
https://ClinicalTrials.gov/show/NCT02273739 |
Completed |
Celgene |
2016-06-30 |
| NCT02232516 |
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02232516 |
Recruiting |
Northwestern University |
2022-07-31 |
| NCT02223208 |
Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02223208 |
Recruiting |
Fondazione Italiana Linfomi ONLUS |
2021-09-30 |
| NCT02192021 |
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT02192021 |
Recruiting |
University of Pittsburgh |
2021-12-31 |
| NCT03385226 |
A Trial Assessing the Effect of Pembrolizumab Combined With Radiotherapy in Patients With Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) |
https://ClinicalTrials.gov/show/NCT03385226 |
Recruiting |
University College, London |
2022-01-31 |
| NCT02181218 |
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas |
https://ClinicalTrials.gov/show/NCT02181218 |
Active, not recruiting |
Washington University School of Medicine |
2019-03-28 |
| NCT02168140 |
CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT02168140 |
Active, not recruiting |
Wake Forest University Health Sciences |
2019-04-18 |
| NCT02158975 |
Open-label, Phase II Study of MLN9708 in Patients With Relapsed/Refractory Cutaneous and Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02158975 |
Completed |
University of Michigan Rogel Cancer Center |
2016-10-31 |
| NCT02106650 |
Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT02106650 |
Completed |
Acrotech Biopharma LLC |
2018-10-31 |
| NCT02085655 |
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma |
https://ClinicalTrials.gov/show/NCT02085655 |
Active, not recruiting |
Sun Yat-sen University |
2018-12-31 |
| NCT01309789 |
A Phase 1 Study of Brentuximab Vedotin Given Sequentially and Combined With Multi-Agent Chemotherapy for CD30-Positive Mature T-Cell and NK-Cell Neoplasms |
https://ClinicalTrials.gov/show/NCT01309789 |
Completed |
Seattle Genetics, Inc. |
2013-04-30 |
| NCT01280526 |
A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01280526 |
Completed |
The Lymphoma Academic Research Organisation |
2012-11-30 |
| NCT01273766 |
Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01273766 |
Completed |
Wake Forest University Health Sciences |
2012-03-31 |
| NCT03770000 |
Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03770000 |
Recruiting |
Rhizen Pharmaceuticals SA |
2020-08-31 |
| NCT02811783 |
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL |
https://ClinicalTrials.gov/show/NCT02811783 |
Recruiting |
Elorac, Inc. |
2022-06-30 |
| NCT02013362 |
Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02013362 |
Completed |
Mundipharma K.K. |
2015-12-31 |
| NCT01991158 |
GAD-M Regimen As First-Line Treatment in Untreated Extranodal NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01991158 |
Active, not recruiting |
Sun Yat-sen University |
2016-12-31 |
| NCT01959477 |
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01959477 |
Completed |
Case Comprehensive Cancer Center |
2015-01-31 |
| NCT01921790 |
Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01921790 |
Recruiting |
Sun Yat-sen University |
2015-08-31 |
| NCT01921387 |
Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01921387 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2017-07-26 |
| NCT01919619 |
Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01919619 |
Recruiting |
M.D. Anderson Cancer Center |
2021-06-30 |
| NCT01908777 |
A Phase 2 Multicenter Study of High Dose Chemotherapy With Autologous Stem Cell Transplant Followed by Maintenance Therapy With Romidepsin for the Treatment of T Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01908777 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-07-31 |
| NCT01902225 |
Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01902225 |
Completed |
University of California, San Francisco |
2018-07-13 |
| NCT01897012 |
Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01897012 |
Completed |
National Cancer Institute (NCI) |
2018-10-31 |
| NCT01871727 |
A Trial of E7777 in Persistent and Recurrent Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01871727 |
Recruiting |
Eisai Inc. |
2021-03-31 |
| NCT01871675 |
Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01871675 |
Completed |
SCRI Development Innovations, LLC |
2016-06-30 |
| NCT01839916 |
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01839916 |
Completed |
University of Chicago |
2018-08-31 |
| NCT01839097 |
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01839097 |
Completed |
Acrotech Biopharma LLC |
2016-01-31 |
| NCT01822886 |
Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT01822886 |
Completed |
Fondazione Italiana Linfomi ONLUS |
2014-12-31 |
| NCT01806337 |
CHO(E)P-14 Followed by Alemtuzumab Consolidation in Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01806337 |
Completed |
University of Göttingen |
2006-07-31 |
| NCT01805037 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
https://ClinicalTrials.gov/show/NCT01805037 |
Active, not recruiting |
Northwestern University |
2021-01-31 |
| NCT01804335 |
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01804335 |
Completed |
M.D. Anderson Cancer Center |
2015-03-31 |
| NCT01804166 |
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn’s Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL) |
https://ClinicalTrials.gov/show/NCT01804166 |
Completed |
Janssen Scientific Affairs, LLC |
2020-02-29 |
| NCT01800838 |
Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01800838 |
Completed |
Case Comprehensive Cancer Center |
2014-09-30 |
| NCT01796002 |
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01796002 |
Active, not recruiting |
The Lymphoma Academic Research Organisation |
2020-03-20 |
| NCT01787409 |
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency |
https://ClinicalTrials.gov/show/NCT01787409 |
Recruiting |
Mayo Clinic |
2020-11-30 |
| NCT01777152 |
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01777152 |
Active, not recruiting |
Seattle Genetics, Inc. |
2018-08-15 |
| NCT01776411 |
Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT01776411 |
Completed |
Mundipharma K.K. |
2016-03-31 |
| NCT01760655 |
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01760655 |
Recruiting |
Thomas Jefferson University |
2021-03-31 |
| NCT01748721 |
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT01748721 |
Completed |
Morphotek |
2015-05-31 |
| NCT01728805 |
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL |
https://ClinicalTrials.gov/show/NCT01728805 |
Active, not recruiting |
Kyowa Kirin Pharmaceutical Development, Inc. |
2017-03-31 |
| NCT01719835 |
CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study |
https://ClinicalTrials.gov/show/NCT01719835 |
Active, not recruiting |
Royal Marsden NHS Foundation Trust |
2016-11-30 |
| NCT01689220 |
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea |
https://ClinicalTrials.gov/show/NCT01689220 |
Completed |
Solasia Pharma K.K. |
2014-01-31 |
| NCT01679860 |
Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01679860 |
Completed |
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
2011-12-31 |
| NCT01678443 |
Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01678443 |
Active, not recruiting |
Fred Hutchinson Cancer Research Center |
2011-04-11 |
| NCT01676831 |
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01676831 |
Completed |
Abramson Cancer Center of the University of Pennsylvania |
2015-01-31 |
| NCT01664975 |
Treatment of Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01664975 |
Completed |
Zhengzhou University |
2016-04-30 |
| NCT01644253 |
Phase 1b Safety and Efficacy Study of TRU-016 |
https://ClinicalTrials.gov/show/NCT01644253 |
Active, not recruiting |
Aptevo Therapeutics |
2020-10-31 |
| NCT01638533 |
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT01638533 |
Active, not recruiting |
National Cancer Institute (NCI) |
2018-11-29 |
| NCT01611142 |
Study of KW-0761 (Mogamulizumab) in Subjects With Previously Treated Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01611142 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2015-05-31 |
| NCT01590732 |
Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01590732 |
Completed |
M.D. Anderson Cancer Center |
2018-05-02 |
| NCT01588015 |
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01588015 |
Active, not recruiting |
City of Hope Medical Center |
2021-11-30 |
| NCT03349333 |
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL |
https://ClinicalTrials.gov/show/NCT03349333 |
Completed |
Mundipharma (China) Pharmaceutical Co. Ltd |
2017-07-21 |
| NCT01578499 |
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician’s Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
https://ClinicalTrials.gov/show/NCT01578499 |
Completed |
Takeda |
2016-05-31 |
| NCT01569724 |
Carbohydrate Metabolism Disorder Frequency in Hypertriglyceridemia Induced by Bexarotene of Cutaneous T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01569724 |
Completed |
Rennes University Hospital |
2016-12-31 |
| NCT01567709 |
Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01567709 |
Completed |
National Cancer Institute (NCI) |
2018-03-29 |
| NCT01561833 |
A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT01561833 |
Completed |
Yale University |
2013-05-31 |
| NCT01529827 |
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01529827 |
Completed |
Roswell Park Cancer Institute |
2015-05-28 |
| NCT01523223 |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT01523223 |
Completed |
Stanford University |
2016-09-30 |
| NCT01486277 |
A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01486277 |
Completed |
Janssen Research & Development, LLC |
2014-11-30 |
| NCT01484015 |
Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia |
https://ClinicalTrials.gov/show/NCT01484015 |
Completed |
Wake Forest University Health Sciences |
2012-06-30 |
| NCT01482962 |
Alisertib (MLN8237) or Investigator’s Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01482962 |
Completed |
Takeda |
2015-06-30 |
| NCT01466881 |
Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01466881 |
Completed |
National Cancer Institute (NCI) |
2014-12-31 |
| NCT01456039 |
A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01456039 |
Completed |
Celgene |
2015-07-28 |
| NCT01445535 |
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01445535 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2011-04-01 |
| NCT01435863 |
A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT01435863 |
Completed |
Solasia Pharma K.K. |
2015-04-30 |
| NCT01433731 |
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01433731 |
Completed |
TetraLogic Pharmaceuticals |
2013-09-30 |
| NCT01431209 |
Ruxolitinib Phosphate in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT01431209 |
Active, not recruiting |
University of Nebraska |
2021-03-31 |
| NCT01427881 |
Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01427881 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-06-30 |
| NCT01421667 |
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01421667 |
Completed |
Seattle Genetics, Inc. |
2015-06-30 |
| NCT01403415 |
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01403415 |
Completed |
National Cancer Institute (NCI) |
2015-05-31 |
| NCT01401530 |
E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01401530 |
Completed |
Eisai Inc. |
2015-08-31 |
| NCT01384513 |
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT01384513 |
Recruiting |
Thomas Jefferson University |
2020-12-31 |
| NCT01336933 |
Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01336933 |
Completed |
University of Nebraska |
2016-12-28 |
| NCT01336920 |
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01336920 |
Completed |
University of Nebraska |
2015-04-30 |
| NCT01326702 |
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors |
https://ClinicalTrials.gov/show/NCT01326702 |
Completed |
National Cancer Institute (NCI) |
2015-04-30 |
| NCT04444141 |
A Study of PD-1/CTLA-4 Bispecific AK104 in Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04444141 |
Recruiting |
Akeso |
2021-06-30 |
| NCT04405375 |
GPED Regimen for Relapsed/Refractory or Advanced ENKTCL |
https://ClinicalTrials.gov/show/NCT04405375 |
Recruiting |
Beijing Tongren Hospital |
2023-04-30 |
| NCT04366128 |
Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL |
https://ClinicalTrials.gov/show/NCT04366128 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2021-12-30 |
| NCT04365036 |
A Multicenter, Phase 3, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL) |
https://ClinicalTrials.gov/show/NCT04365036 |
Recruiting |
Sun Yat-sen University |
2025-04-30 |
| NCT04362007 |
A Phase I/II Study of ASTX660 in Patients With Relapsed or Refractory T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04362007 |
Recruiting |
Otsuka Pharmaceutical Co., Ltd. |
2024-09-30 |
| NCT04334174 |
Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas |
https://ClinicalTrials.gov/show/NCT04334174 |
Recruiting |
University of Kansas Medical Center |
2023-04-30 |
| NCT04329130 |
Chidamide Combination With Lenalidomide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04329130 |
Recruiting |
Sun Yat-sen University |
2022-03-26 |
| NCT04296786 |
Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II Study |
https://ClinicalTrials.gov/show/NCT04296786 |
Recruiting |
Peking Union Medical College Hospital |
2022-12-31 |
| NCT04279379 |
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04279379 |
Recruiting |
Beijing Tongren Hospital |
2022-12-31 |
| NCT04231370 |
Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04231370 |
Recruiting |
Beijing Tongren Hospital |
2022-02-28 |
| NCT04230330 |
Nivolumab in Combination With GDP/ L-asparaginase in NK/ T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04230330 |
Recruiting |
National Cancer Centre, Singapore |
2022-01-31 |
| NCT04219319 |
LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04219319 |
Recruiting |
The First Affiliated Hospital with Nanjing Medical University |
2022-11-29 |
| NCT03372057 |
A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT03372057 |
Recruiting |
Verastem, Inc. |
2021-11-30 |
| NCT04171791 |
A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT04171791 |
Recruiting |
Yale University |
2021-02-28 |
| NCT04127227 |
Sintilimab With P-GemOx Regimen for Newly Diagnosed Advanced Extranodal Natural Killer/T-cell Lymphoma, Nasal Type |
https://ClinicalTrials.gov/show/NCT04127227 |
Recruiting |
Sun Yat-sen University |
2023-10-09 |
| NCT04121507 |
ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy |
https://ClinicalTrials.gov/show/NCT04121507 |
Recruiting |
GWT-TUD GmbH |
2020-03-30 |
| NCT04105010 |
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8) |
https://ClinicalTrials.gov/show/NCT04105010 |
Recruiting |
Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
2020-12-31 |
| NCT04101331 |
Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT04101331 |
Recruiting |
Affimed GmbH |
2022-04-30 |
| NCT04096690 |
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04096690 |
Recruiting |
Ruijin Hospital |
2021-12-31 |
| NCT04083495 |
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04083495 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2021-09-30 |
| NCT04061772 |
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04061772 |
Recruiting |
Zhejiang Cancer Hospital |
2021-07-05 |
| NCT04045470 |
A Pilot of a Microdevice For In Situ Candidate Drug Screening in Cutaneous Lesions of T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04045470 |
Recruiting |
Dana-Farber Cancer Institute |
2023-01-01 |
| NCT04040491 |
PD-1 Antibody, Chidamide, Lenalidomide and Gemcitabine for Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04040491 |
Recruiting |
Zhengzhou University |
2020-12-01 |
| NCT04038411 |
PD-1 Antibody, Chidamide, Lenalidomide and Etoposide for Relapsed or Refractory NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04038411 |
Recruiting |
Zhengzhou University |
2021-04-01 |
| NCT04008394 |
Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies |
https://ClinicalTrials.gov/show/NCT04008394 |
Recruiting |
Wuhan Union Hospital, China |
2022-07-01 |
| NCT04004637 |
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia |
https://ClinicalTrials.gov/show/NCT04004637 |
Recruiting |
PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
2021-06-01 |
| NCT04004572 |
Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT04004572 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-12-30 |
| NCT03952572 |
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03952572 |
Recruiting |
Peking University |
2023-04-30 |
| NCT03952078 |
A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03952078 |
Recruiting |
Corvus Pharmaceuticals, Inc. |
2020-12-31 |
| NCT03936452 |
Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03936452 |
Recruiting |
Sun Yat-sen University |
2020-04-30 |
| NCT03927105 |
Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03927105 |
Active, not recruiting |
Big Ten Cancer Research Consortium |
2024-05-31 |
| NCT03922724 |
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03922724 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2023-05-27 |
| NCT03921879 |
Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT03921879 |
Recruiting |
Oncotartis, Inc. |
2021-04-30 |
| NCT03905135 |
Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies |
https://ClinicalTrials.gov/show/NCT03905135 |
Recruiting |
National Institutes of Health Clinical Center (CC) |
2022-03-01 |
| NCT03902184 |
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03902184 |
Recruiting |
Innate Pharma |
2022-03-01 |
| NCT03853044 |
Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03853044 |
Recruiting |
Ruijin Hospital |
2020-12-31 |
| NCT03837457 |
PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study |
https://ClinicalTrials.gov/show/NCT03837457 |
Enrolling by invitation |
miRagen Therapeutics, Inc. |
2021-12-31 |
| NCT03833180 |
A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT03833180 |
Recruiting |
VelosBio Inc. |
2021-03-31 |
| NCT03789617 |
Clinical Trial to Evaluate the Efficacy and Safety of Epstein-Barr Virus Induced Natural T Lymphocyte(EBViNT) Cell in Patients With Progressive EBV Positive Extranodal NK/T-cell Lymphoma Where Standard Treatments Have Failed |
https://ClinicalTrials.gov/show/NCT03789617 |
Recruiting |
Eutilex |
2020-09-30 |
| NCT03775525 |
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT03775525 |
Recruiting |
Genzada Pharmaceuticals USA, Inc. |
2020-09-30 |
| NCT03730740 |
Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03730740 |
Recruiting |
Samsung Medical Center |
2021-11-15 |
| NCT03728972 |
Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type |
https://ClinicalTrials.gov/show/NCT03728972 |
Recruiting |
Memorial Sloan Kettering Cancer Center |
2021-11-30 |
| NCT03713320 |
SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides |
https://ClinicalTrials.gov/show/NCT03713320 |
Active, not recruiting |
miRagen Therapeutics, Inc. |
2021-04-30 |
| NCT03703375 |
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03703375 |
Recruiting |
Celgene |
2021-12-31 |
| NCT03671850 |
VT-EBV-N for Treatment of Severe in EBV Positive Extranodal NK/T Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03671850 |
Recruiting |
ViGenCell Inc. |
2023-12-04 |
| NCT03631862 |
Treatment of Newly Diagnosed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03631862 |
Recruiting |
Zhengzhou University |
2019-12-31 |
| NCT03630731 |
Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03630731 |
Recruiting |
Chinese Academy of Medical Sciences |
2020-03-31 |
| NCT03623087 |
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia |
https://ClinicalTrials.gov/show/NCT03623087 |
Recruiting |
The University of Hong Kong |
2020-03-14 |
| NCT03618238 |
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03618238 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-12-31 |
| NCT03617432 |
Chidamide Combined With CHOPE Regimen for Peripheral T-cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT03617432 |
Recruiting |
Peking University |
2020-09-30 |
| NCT03602157 |
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL |
https://ClinicalTrials.gov/show/NCT03602157 |
Recruiting |
UNC Lineberger Comprehensive Cancer Center |
2026-09-30 |
| NCT03601819 |
Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders |
https://ClinicalTrials.gov/show/NCT03601819 |
Recruiting |
University of Michigan Rogel Cancer Center |
2021-09-30 |
| NCT03598998 |
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03598998 |
Recruiting |
City of Hope Medical Center |
2021-04-27 |
| NCT03593018 |
Efficacy and Safety of Oral Azacitidine Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory AITL |
https://ClinicalTrials.gov/show/NCT03593018 |
Recruiting |
The Lymphoma Academic Research Organisation |
2021-12-31 |
| NCT03590574 |
Phase I/II Study Evaluating AUTO4 in Patients With TRBC1 Positive T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03590574 |
Recruiting |
Autolus Limited |
2021-07-31 |
| NCT03586999 |
Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03586999 |
Recruiting |
University of Colorado, Denver |
2020-08-31 |
| NCT03586024 |
Pembrolizumab in Relapsed or Refractory Extranodal NK/T- Cell Lymphoma, Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT03586024 |
Active, not recruiting |
Abramson Cancer Center of the University of Pennsylvania |
2022-03-12 |
| NCT03547700 |
Study of Ixazomib and Romidepsin in Peripheral T-cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT03547700 |
Recruiting |
Big Ten Cancer Research Consortium |
2020-07-31 |
| NCT03542266 |
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03542266 |
Active, not recruiting |
Weill Medical College of Cornell University |
2020-03-25 |
| NCT03534180 |
Venetoclax in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03534180 |
Recruiting |
City of Hope Medical Center |
2020-08-21 |
| NCT03502629 |
Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226) |
https://ClinicalTrials.gov/show/NCT03502629 |
Recruiting |
Genor Biopharma Co., Ltd. |
2020-08-31 |
| NCT03501576 |
Evaluation of Human Immune Responses to Influenza Virus Vaccination in Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT03501576 |
Recruiting |
Emory University |
2021-04-30 |
| NCT03496779 |
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine |
https://ClinicalTrials.gov/show/NCT03496779 |
Recruiting |
The Lymphoma Academic Research Organisation |
2020-03-31 |
| NCT03493451 |
Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK- Neoplasms |
https://ClinicalTrials.gov/show/NCT03493451 |
Active, not recruiting |
BeiGene |
2021-02-28 |
| NCT03487133 |
Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03487133 |
Recruiting |
Samsung Medical Center |
2020-12-31 |
| NCT03439501 |
Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY] |
https://ClinicalTrials.gov/show/NCT03439501 |
Active, not recruiting |
Samsung Medical Center |
2021-04-24 |
| NCT01261247 |
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01261247 |
Active, not recruiting |
Mayo Clinic |
2016-05-09 |
| NCT01258998 |
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma |
https://ClinicalTrials.gov/show/NCT01258998 |
Completed |
National Cancer Institute (NCI) |
2014-07-31 |
| NCT01254578 |
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers |
https://ClinicalTrials.gov/show/NCT01254578 |
Completed |
National Cancer Institute (NCI) |
2012-11-09 |
| NCT01238159 |
Concomitant Chemo-radiotherapy Followed by MIDLE Chemotherapy in Stage I/II Extranodal NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01238159 |
Completed |
Samsung Medical Center |
2014-12-31 |
| NCT01233921 |
Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT01233921 |
Completed |
Fred Hutchinson Cancer Research Center |
2012-07-31 |
| NCT01226472 |
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 |
https://ClinicalTrials.gov/show/NCT01226472 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2012-09-30 |
| NCT01198665 |
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT01198665 |
Completed |
Samsung Medical Center |
2014-12-31 |
| NCT01177371 |
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01177371 |
Completed |
Case Comprehensive Cancer Center |
2000-02-29 |
| NCT01169298 |
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01169298 |
Completed |
Celgene |
2013-12-01 |
| NCT01158274 |
RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors |
https://ClinicalTrials.gov/show/NCT01158274 |
Completed |
National Cancer Institute (NCI) |
2012-08-31 |
| NCT01155817 |
Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease |
https://ClinicalTrials.gov/show/NCT01155817 |
Completed |
Stanford University |
2013-12-31 |
| NCT01134341 |
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01134341 |
Completed |
Acrotech Biopharma LLC |
2015-08-31 |
| NCT01129193 |
AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma |
https://ClinicalTrials.gov/show/NCT01129193 |
Completed |
Ohio State University Comprehensive Cancer Center |
2017-01-07 |
| NCT01129180 |
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01129180 |
Completed |
Ohio State University Comprehensive Cancer Center |
2012-05-31 |
| NCT01110135 |
Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT01110135 |
Completed |
University of Washington |
2013-11-30 |
| NCT01093586 |
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01093586 |
Completed |
Case Comprehensive Cancer Center |
2015-12-31 |
| NCT01076543 |
Lenalidomide and Temsirolimus in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01076543 |
Completed |
National Cancer Institute (NCI) |
2017-12-31 |
| NCT01075321 |
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01075321 |
Active, not recruiting |
Mayo Clinic |
2015-02-28 |
| NCT01053494 |
Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer |
https://ClinicalTrials.gov/show/NCT01053494 |
Completed |
Wake Forest University Health Sciences |
2012-02-29 |
| NCT01007526 |
Concomitant Chemo-radiotherapy Plus VIDL Chemotherapy in NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT01007526 |
Completed |
Samsung Medical Center |
2012-12-31 |
| NCT01007448 |
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT01007448 |
Completed |
Bausch Health Americas, Inc. |
2014-02-20 |
| NCT00992446 |
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00992446 |
Completed |
Fred Hutchinson Cancer Research Center |
2015-06-17 |
| NCT00970385 |
Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00970385 |
Completed |
University Hospital, Grenoble |
2002-12-31 |
| NCT00963274 |
Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
https://ClinicalTrials.gov/show/NCT00963274 |
Completed |
Virginia Commonwealth University |
2014-07-17 |
| NCT00961220 |
O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00961220 |
Completed |
National Cancer Institute (NCI) |
2012-04-08 |
| NCT00959686 |
Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00959686 |
Completed |
French Innovative Leukemia Organisation |
2011-06-30 |
| NCT00930605 |
The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL) |
https://ClinicalTrials.gov/show/NCT00930605 |
Completed |
King Chulalongkorn Memorial Hospital |
2006-11-30 |
| NCT00918333 |
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00918333 |
Completed |
Mayo Clinic |
2015-12-01 |
| NCT00901147 |
Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00901147 |
Completed |
Singapore General Hospital |
2014-01-31 |
| NCT00896493 |
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00896493 |
Active, not recruiting |
Stanford University |
2022-12-31 |
| NCT00891072 |
Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery |
https://ClinicalTrials.gov/show/NCT00891072 |
Completed |
National Cancer Institute (NCI) |
2011-04-30 |
| NCT00890747 |
Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
https://ClinicalTrials.gov/show/NCT00890747 |
Completed |
National Cancer Institute (NCI) |
2011-05-31 |
| NCT00888927 |
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00888927 |
Completed |
Kyowa Kirin Pharmaceutical Development, Inc. |
2012-09-30 |
| NCT00880815 |
Fludarabine, Bendamustine, and Rituximab in Treating Participants With Lymphoid Cancers Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00880815 |
Completed |
M.D. Anderson Cancer Center |
2019-05-28 |
| NCT00877656 |
HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00877656 |
Completed |
Emergent BioSolutions |
2006-01-31 |
| NCT00865969 |
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00865969 |
Completed |
Spectrum Pharmaceuticals, Inc |
2014-10-31 |
| NCT00856388 |
Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders |
https://ClinicalTrials.gov/show/NCT00856388 |
Completed |
Roswell Park Cancer Institute |
2012-08-09 |
| NCT00854425 |
L-asparaginase Monotherapy as Salvage Treatment in Patients With NK/T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00854425 |
Completed |
Fudan University |
2012-01-31 |
| NCT04319601 |
Rituximab Combined With Chidamide and Lenalidomide for r/r AITL |
https://ClinicalTrials.gov/show/NCT04319601 |
Recruiting |
Zhejiang Cancer Hospital |
2022-03-31 |
| NCT03595657 |
A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03595657 |
Recruiting |
CStone Pharmaceuticals |
2020-12-31 |
| NCT02544425 |
VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma (VIDL+ASCT) |
https://ClinicalTrials.gov/show/NCT02544425 |
Recruiting |
Samsung Medical Center |
2019-11-30 |
| NCT00807495 |
Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00807495 |
Completed |
Takeda |
2011-01-04 |
| NCT01658319 |
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT01658319 |
Completed |
Case Comprehensive Cancer Center |
2015-02-28 |
| NCT01553786 |
Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) |
https://ClinicalTrials.gov/show/NCT01553786 |
Completed |
The Lymphoma Academic Research Organisation |
2018-03-31 |
| NCT02953301 |
Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) |
https://ClinicalTrials.gov/show/NCT02953301 |
Recruiting |
4SC AG |
2022-01-31 |
| NCT03061188 |
Nivolumab and Veliparib in Treating Patients With Recurrent or Refractory Stage IV Solid Tumors That Cannot Be Removed by Surgery or Lymphoma With or Without Alterations in DNA Repair Genes |
https://ClinicalTrials.gov/show/NCT03061188 |
Active, not recruiting |
Northwestern University |
2020-09-30 |
| NCT02580552 |
Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL |
https://ClinicalTrials.gov/show/NCT02580552 |
Active, not recruiting |
miRagen Therapeutics, Inc. |
2020-12-31 |
| NCT02733458 |
GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT02733458 |
Recruiting |
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine |
2020-12-31 |
| NCT02341014 |
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas |
https://ClinicalTrials.gov/show/NCT02341014 |
Active, not recruiting |
Memorial Sloan Kettering Cancer Center |
2021-01-31 |
| NCT01701986 |
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT01701986 |
Recruiting |
M.D. Anderson Cancer Center |
2020-05-01 |
| NCT03776279 |
A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT03776279 |
Recruiting |
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
2020-12-30 |
| NCT00791947 |
A Nordic Phase II Study of PTCL Based on Dose-intensive Induction and High-dose Consolidation With ASCT |
https://ClinicalTrials.gov/show/NCT00791947 |
Completed |
University of Aarhus |
2008-08-31 |
| NCT00787527 |
SAHA + CHOP in Untreated T-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00787527 |
Completed |
M.D. Anderson Cancer Center |
2012-12-31 |
| NCT00771472 |
Vorinostat (MK-0683) Phase I Study in Cutaneous T-Cell Lymphoma (CTCL) Patients (MK-0683-089 EXT1) |
https://ClinicalTrials.gov/show/NCT00771472 |
Completed |
Merck Sharp & Dohme Corp. |
2011-07-31 |
| NCT00769288 |
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00769288 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00748319 |
Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00748319 |
Completed |
Assistance Publique - Hôpitaux de Paris |
2011-11-30 |
| NCT00744991 |
A Study for Patients With Relapsed Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00744991 |
Completed |
Eli Lilly and Company |
2010-01-31 |
| NCT00723099 |
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00723099 |
Completed |
Fred Hutchinson Cancer Research Center |
2018-07-31 |
| NCT00697346 |
Study of MLN8237 in Participants With Advanced Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00697346 |
Completed |
Takeda |
2016-10-01 |
| NCT00684411 |
Gleevec in Relapsed/Refractory T Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00684411 |
Completed |
Dana-Farber Cancer Institute |
2013-10-31 |
| NCT00660231 |
Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00660231 |
Completed |
University College, London |
2011-09-30 |
| NCT00646854 |
Alemtuzumab and CHOP in T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00646854 |
Completed |
University of Aarhus |
2016-12-31 |
| NCT00644189 |
Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma |
https://ClinicalTrials.gov/show/NCT00644189 |
Active, not recruiting |
Massachusetts General Hospital |
2013-12-31 |
| NCT00611208 |
A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT00611208 |
Completed |
Angimmune LLC |
2015-02-28 |
| NCT00608361 |
Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery |
https://ClinicalTrials.gov/show/NCT00608361 |
Completed |
National Cancer Institute (NCI) |
2014-08-31 |
| NCT00601718 |
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00601718 |
Completed |
University of Washington |
2010-06-30 |
| NCT00554827 |
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00554827 |
Completed |
Acrotech Biopharma LLC |
2012-01-31 |
| NCT00536601 |
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors |
https://ClinicalTrials.gov/show/NCT00536601 |
Completed |
Roswell Park Cancer Institute |
2018-07-09 |
| NCT00506129 |
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00506129 |
Completed |
M.D. Anderson Cancer Center |
2015-06-30 |
| NCT00501735 |
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00501735 |
Completed |
BioCryst Pharmaceuticals |
2010-07-31 |
| NCT00499811 |
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00499811 |
Completed |
National Cancer Institute (NCI) |
2011-08-31 |
| NCT00490776 |
Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00490776 |
Completed |
Novartis |
2009-09-30 |
| NCT00489203 |
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00489203 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00481871 |
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies |
https://ClinicalTrials.gov/show/NCT00481871 |
Completed |
Acrotech Biopharma LLC |
2011-05-31 |
| NCT00458731 |
Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma |
https://ClinicalTrials.gov/show/NCT00458731 |
Completed |
National Cancer Institute (NCI) |
2013-12-31 |
| NCT00453427 |
Alemtuzumab and CHOP Chemotherapy for Aggressive Histological Peripheral T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00453427 |
Completed |
Ontario Clinical Oncology Group (OCOG) |
2013-06-30 |
| NCT00438802 |
Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00438802 |
Completed |
Mayo Clinic |
2010-08-24 |
| NCT00431912 |
A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00431912 |
Completed |
Onxeo |
2011-01-31 |
| NCT00426764 |
A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00426764 |
Completed |
Celgene |
2010-11-11 |
| NCT00425555 |
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00425555 |
Completed |
Novartis |
2013-06-30 |
| NCT00418535 |
Clinical Study of Chemoradiation Followed by VIPD in Nasal Natural Killer (NK)/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00418535 |
Completed |
Samsung Medical Center |
2009-03-31 |
| NCT00412997 |
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00412997 |
Completed |
Novartis |
2008-05-31 |
| NCT00408681 |
Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00408681 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-11-30 |
| NCT00406809 |
A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00406809 |
Completed |
AbbVie |
2016-10-31 |
| NCT00799461 |
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications |
https://ClinicalTrials.gov/show/NCT00799461 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-11-30 |
| NCT00374699 |
Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00374699 |
Completed |
Samsung Medical Center |
2009-09-30 |
| NCT00364923 |
Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00364923 |
Completed |
Acrotech Biopharma LLC |
2009-01-31 |
| NCT00355472 |
Phase I Study of KW-0761 in Relapsed Patients With CCR4-Positive ATL and PTCL |
https://ClinicalTrials.gov/show/NCT00355472 |
Completed |
Kyowa Kirin Co., Ltd. |
2008-10-31 |
| NCT00348985 |
PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00348985 |
Completed |
National Cancer Institute (NCI) |
2010-01-31 |
| NCT00343798 |
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00343798 |
Completed |
Fred Hutchinson Cancer Research Center |
2013-07-31 |
| NCT00337987 |
A Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00337987 |
Completed |
Yale University |
2007-12-31 |
| NCT00336063 |
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00336063 |
Active, not recruiting |
National Cancer Institute (NCI) |
2013-04-19 |
| NCT00322985 |
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00322985 |
Completed |
AHS Cancer Control Alberta |
2014-05-31 |
| NCT00306969 |
Study of Oral Bexarotene in Combination With Photopheresis for Treatment of Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00306969 |
Completed |
Boston University |
NA |
| NCT00293345 |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00293345 |
Completed |
National Cancer Institute (NCI) |
2012-10-31 |
| NCT00292695 |
A Phase II Study of Nasal NK/T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00292695 |
Completed |
National Health Research Institutes, Taiwan |
2009-12-31 |
| NCT00290433 |
Efficacy of the HCVIDDOXIL Regimen in Patients With Newly Diagnosed Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00290433 |
Completed |
M.D. Anderson Cancer Center |
2015-07-31 |
| NCT00283985 |
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00283985 |
Completed |
University Hospital, Limoges |
2012-06-30 |
| NCT00255801 |
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00255801 |
Completed |
Memorial Sloan Kettering Cancer Center |
2017-10-31 |
| NCT00221039 |
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A |
https://ClinicalTrials.gov/show/NCT00221039 |
Completed |
M.D. Anderson Cancer Center |
2011-04-05 |
| NCT00211198 |
Study of ONTAK® to Treat Cutaneous T-Cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT00211198 |
Completed |
Eisai Inc. |
2005-01-31 |
| NCT00211185 |
A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00211185 |
Completed |
Eisai Inc. |
2008-08-31 |
| NCT00182637 |
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00182637 |
Completed |
Jonsson Comprehensive Cancer Center |
2010-09-30 |
| NCT00178841 |
Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL |
https://ClinicalTrials.gov/show/NCT00178841 |
Completed |
Vanderbilt University |
2007-03-31 |
| NCT00136565 |
Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00136565 |
Completed |
Lymphoma Study Association |
2011-04-18 |
| NCT00131937 |
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00131937 |
Completed |
National Cancer Institute (NCI) |
2011-09-30 |
| NCT00118352 |
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00118352 |
Completed |
Fred Hutchinson Cancer Research Center |
2010-07-31 |
| NCT00112593 |
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
https://ClinicalTrials.gov/show/NCT00112593 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-11-30 |
| NCT00109928 |
S0350 Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin’s Lymphoma |
https://ClinicalTrials.gov/show/NCT00109928 |
Completed |
Southwest Oncology Group |
2012-06-30 |
| NCT00106431 |
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) |
https://ClinicalTrials.gov/show/NCT00106431 |
Completed |
Celgene |
2008-06-01 |
| NCT00099593 |
Immunization Against Tumor Cells in Sezary Syndrome |
https://ClinicalTrials.gov/show/NCT00099593 |
Completed |
FDA Office of Orphan Products Development |
NA |
| NCT00098891 |
MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00098891 |
Completed |
National Cancer Institute (NCI) |
2008-03-31 |
| NCT00098332 |
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00098332 |
Completed |
National Cancer Institute (NCI) |
2010-12-31 |
| NCT00091559 |
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) |
https://ClinicalTrials.gov/show/NCT00091559 |
Completed |
Merck Sharp & Dohme Corp. |
2005-11-23 |
| NCT00002635 |
Aminocamptothecin in Treating Patients With T-cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00002635 |
Completed |
Yale University |
2000-04-30 |
| NCT00089271 |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas |
https://ClinicalTrials.gov/show/NCT00089271 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00089011 |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00089011 |
Completed |
Fred Hutchinson Cancer Research Center |
2014-03-31 |
| NCT00003196 |
Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma |
https://ClinicalTrials.gov/show/NCT00003196 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-04-30 |
| NCT00798096 |
Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00798096 |
Completed |
Rigel Pharmaceuticals |
2010-04-30 |
| NCT00006251 |
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer |
https://ClinicalTrials.gov/show/NCT00006251 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-09-30 |
| NCT00082888 |
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma |
https://ClinicalTrials.gov/show/NCT00082888 |
Completed |
National Cancer Institute (NCI) |
2009-05-20 |
| NCT00005080 |
506U78 in Treating Patients With Lymphoma |
https://ClinicalTrials.gov/show/NCT00005080 |
Completed |
National Cancer Institute (NCI) |
2006-01-31 |
| NCT00080535 |
Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00080535 |
Completed |
National Institutes of Health Clinical Center (CC) |
2011-12-31 |
| NCT00005799 |
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer |
https://ClinicalTrials.gov/show/NCT00005799 |
Completed |
Fred Hutchinson Cancer Research Center |
2002-07-31 |
| NCT00006345 |
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00006345 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00078858 |
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00078858 |
Completed |
Fred Hutchinson Cancer Research Center |
2006-01-31 |
| NCT00077155 |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00077155 |
Completed |
National Cancer Institute (NCI) |
2010-06-30 |
| NCT00072514 |
Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00072514 |
Completed |
Fred Hutchinson Cancer Research Center |
2008-07-31 |
| NCT00071084 |
Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. |
https://ClinicalTrials.gov/show/NCT00071084 |
Completed |
Emergent Product Development Seattle LLC |
2004-06-30 |
| NCT00071071 |
Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. |
https://ClinicalTrials.gov/show/NCT00071071 |
Completed |
Emergent Product Development Seattle LLC |
2004-05-31 |
| NCT00069238 |
Campath-1H and EPOCH to Treat Non-Hodgkin’s T- and NK-Cell Lymphomas |
https://ClinicalTrials.gov/show/NCT00069238 |
Active, not recruiting |
National Institutes of Health Clinical Center (CC) |
2009-06-11 |
| NCT00003210 |
Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease |
https://ClinicalTrials.gov/show/NCT00003210 |
Completed |
National Cancer Institute (NCI) |
2003-11-30 |
| NCT00061880 |
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00061880 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00049504 |
Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer |
https://ClinicalTrials.gov/show/NCT00049504 |
Completed |
Fred Hutchinson Cancer Research Center |
2011-03-31 |
| NCT00040846 |
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies |
https://ClinicalTrials.gov/show/NCT00040846 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-12-31 |
| NCT00030849 |
Bexarotene and Interferon Alfa in Treating Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00030849 |
Completed |
National Cancer Institute (NCI) |
2004-09-30 |
| NCT00795769 |
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant |
https://ClinicalTrials.gov/show/NCT00795769 |
Completed |
Fred Hutchinson Cancer Research Center |
2009-06-09 |
| NCT00020072 |
Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells |
https://ClinicalTrials.gov/show/NCT00020072 |
Completed |
National Cancer Institute (NCI) |
NA |
| NCT00014235 |
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00014235 |
Completed |
Fred Hutchinson Cancer Research Center |
2005-02-28 |
| NCT00004241 |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma |
https://ClinicalTrials.gov/show/NCT00004241 |
Completed |
National Cancer Institute (NCI) |
2006-05-31 |
| NCT00051597 |
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies |
https://ClinicalTrials.gov/show/NCT00051597 |
Completed |
Seattle Genetics, Inc. |
NA |
| NCT00051012 |
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients |
https://ClinicalTrials.gov/show/NCT00051012 |
Completed |
Eisai Inc. |
2006-10-31 |
| NCT00050999 |
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients |
https://ClinicalTrials.gov/show/NCT00050999 |
Completed |
Eisai Inc. |
2006-09-30 |
| NCT00001249 |
Treatment of Tac-Expressing Cutaneous T-Cell Lymphoma (CTCL) and Adult T-Cell Leukemia (ATL) With Yttrium-90 Radiolabeled Anti-Tac |
https://ClinicalTrials.gov/show/NCT00001249 |
Completed |
National Institutes of Health Clinical Center (CC) |
NA |
| NCT00043420 |
CPG 7909 in Patients With Cutaneous T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00043420 |
Completed |
Pfizer |
2007-03-31 |
| NCT00043368 |
PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909) |
https://ClinicalTrials.gov/show/NCT00043368 |
Completed |
Pfizer |
2007-06-30 |
| NCT00038376 |
Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies |
https://ClinicalTrials.gov/show/NCT00038376 |
Completed |
M.D. Anderson Cancer Center |
2005-06-30 |
| NCT00038025 |
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies |
https://ClinicalTrials.gov/show/NCT00038025 |
Completed |
M.D. Anderson Cancer Center |
2006-11-29 |
| NCT00003970 |
Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma |
https://ClinicalTrials.gov/show/NCT00003970 |
Completed |
National Cancer Institute (NCI) |
2003-10-31 |
| NCT00025415 |
Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction |
https://ClinicalTrials.gov/show/NCT00025415 |
Completed |
National Cancer Institute (NCI) |
2005-01-31 |
| NCT00007345 |
Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma |
https://ClinicalTrials.gov/show/NCT00007345 |
Completed |
National Institutes of Health Clinical Center (CC) |
2015-01-26 |